Menu
Search
|

Menu

Close
X

Ablynx NV ABLX.OQ (NASDAQ Stock Exchange Global Select Market)

53.95 USD
+0.04 (+0.07%)
As of 2:29 AM IST
chart
Previous Close 53.91
Open 53.92
Volume 19,847
3m Avg Volume --
Today’s High 54.03
Today’s Low 53.85
52 Week High 54.87
52 Week Low 17.75
Shares Outstanding (mil) 61.42
Market Capitalization (mil) 987.62
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.40 Mean rating from 5 analysts

KEY STATS

Revenue (mm, EUR)
FY17
35
FY16
85
FY15
78
EPS (EUR)
FY17
-0.420
FY16
0.010
FY15
-1.002
*Note: Units in Millions of Euro
**Note: Units in Euro

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
14.88
5.77
Price to Book (MRQ)
vs sector
12.18
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
107.61
16.52
LT Debt to Equity (MRQ)
vs sector
107.61
12.22
Return on Investment (TTM)
vs sector
-23.57
14.43
Return on Equity (TTM)
vs sector
-47.81
16.13

EXECUTIVE LEADERSHIP

Russell Greig
Chairman of the Board, Since 2018
Salary: --
Bonus: --
Edwin Moses
Chief Executive Officer, Director, Since 2013
Salary: €362,115.00
Bonus: €92,963.00
Wim Ottevaere
Chief Financial Officer, Since
Salary: --
Bonus: --
Kim Simonsen
Chief Operations Officer, Since
Salary: --
Bonus: --
Frank Landolt
Vice President - Intellectual Property, and Legal, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Technologiepark-Zwijnaarde 21
GENT     9052

Phone: +329.2620000

Ablynx NV is a Belgium-based biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx NV has more than 30 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co, Inc., Merck Serono and Novartis.

SPONSORED STORIES